Kymera Therapeutics, Inc. (KYMR)

NASDAQ: KYMR · Real-Time Price · USD
30.77
+1.66 (5.70%)
May 8, 2025, 4:00 PM EDT - Market closed
5.70%
Market Cap 2.00B
Revenue (ttm) 47.07M
Net Income (ttm) -223.86M
Shares Out 64.94M
EPS (ttm) -2.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 670,158
Open 28.57
Previous Close 29.11
Day's Range 28.40 - 31.15
52-Week Range 19.45 - 53.27
Beta 2.19
Analysts Buy
Price Target 56.69 (+84.24%)
Earnings Date May 9, 2025

About KYMR

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat aut... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 21, 2020
Employees 188
Stock Exchange NASDAQ
Ticker Symbol KYMR
Full Company Profile

Financial Performance

In 2024, Kymera Therapeutics's revenue was $47.07 million, a decrease of -40.11% compared to the previous year's $78.59 million. Losses were -$223.86 million, 52.3% more than in 2023.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $56.69, which is an increase of 84.24% from the latest price.

Price Target
$56.69
(84.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

1 day ago - GlobeNewsWire

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June ...

16 days ago - GlobeNewsWire

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...

4 weeks ago - GlobeNewsWire

Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Fou...

2 months ago - Seeking Alpha

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

2 months ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) --   Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicin...

3 months ago - GlobeNewsWire

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and pla...

4 months ago - GlobeNewsWire

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

4 months ago - GlobeNewsWire

Kymera: Protein Degradation Could Drive Dupixent-Like Value

Kymera Therapeutics' KT-474, partnered with Sanofi, is in Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis, with completion of studies expected mid-2026. KT-621, a STAT6 degrader for ...

5 months ago - Seeking Alpha

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

5 months ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

6 months ago - GlobeNewsWire

Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President & CEO Jared ...

6 months ago - Seeking Alpha

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025

6 months ago - GlobeNewsWire

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases

7 months ago - GlobeNewsWire

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

7 months ago - GlobeNewsWire

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

7 months ago - GlobeNewsWire

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases

7 months ago - GlobeNewsWire

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Kymera Therapeutics' innovative TPD technology degrades disease-causing proteins, with promising candidates like KT-474 and KT-621 targeting large TAMs in immunology and oncology. The company's approa...

7 months ago - Seeking Alpha

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease

8 months ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

9 months ago - GlobeNewsWire

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

9 months ago - GlobeNewsWire

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

9 months ago - GlobeNewsWire

Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

9 months ago - GlobeNewsWire

Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Justine Koenigsberg - Vice President, Investor Relations Nello Mainolfi - Found...

9 months ago - Seeking Alpha

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

10 months ago - GlobeNewsWire